Opendata, web and dolomites

SIROCO SIGNED

Sparing gene therapy for Inherited ROd COne dystrophies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SIROCO project word cloud

Explore the words cloud of the SIROCO project. It provides you a very rough idea of what is the project "SIROCO" about.

inherited    sme    money    team    many    blindness    accessible    siroco    treatment    treating    retina    pathology    cone    primarily    finalize    ip    2004    young    leveillard    progressive    vision    mice    forms    renamed    subsequent    injected    secured    disorders    ophthalmology    world    patients    65    treat    mutations    diseases    agreements    small    million    almost    retinitis    degeneration    remaining    dysfunction    repair    supporting    retinal    causes    genetic    clinical    therapeutic    pursue    sahel    innovative    degenerative    raised    validation    proof    group    sparingvision    neurotrophic    exclusive    gene    unnecessary    lasting    adults    rod    photoreceptor    evolution    stopped    diffuse    people    solution    amd    believe    option    rare    protection    single    models    tomorrow    pigmentosa    patents    injection    saving    potentially    stop    licenses    cones    board    rdcvf    instrument    scientific    first    photoreceptors    rp    efficacy    leads    corrective    disease    dry    therapy    advisory   

Project "SIROCO" data sheet

The following table provides information about the project.

Coordinator
SPARINGVISION 

Organization address
address: 55 RUE DE LYON
city: PARIS
postcode: 75012
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 3˙529˙593 €
 EC max contribution 2˙470˙715 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SPARINGVISION FR (PARIS) coordinator 2˙470˙715.00

Map

 Project objective

Many believe that corrective ophthalmology gene therapy is the future for rare diseases such as retinitis pigmentosa (RP), a rare, inherited retinal disorders characterized by diffuse progressive dysfunction of primarily rod photoreceptors, with subsequent degeneration of cone photoreceptors. This degenerative disease causes blindness to young people and adults. But with this kind of therapy only treating 1 out of 65 mutations of the pathology, it means a small group of patents can be targeted. So, what do the remaining 2 million people have as on option? SparingVision have developed an innovative treatment that can stop the evolution of this blindness and we call it RdCVF. The first vision saving treatment of its kind. What makes it different is that in 2004, J Sahel and T Leveillard identified that in RP, the main factor that leads to blindness is a loss of RdCVF with is a neurotrophic factor for the cones (photoreceptor). This means that by a single injection under the retina SparingVision’ product can treat all the genetic forms of RP, potentially treat patients with dry AMD, and provide patients with long lasting efficacy. In SparingVision’ proof of concept the product was injected to mice models provided almost immediate protection and repair to the cones and the evolution to blindness is stopped. Behind this product is a very strong team, a world renamed scientific advisory board. The product development has been secured with strong IP, exclusive licenses agreements and pursue R&D with research collaboration agreements and raised money. So, tomorrow with the help of SME INSTRUMENT supporting the project SIROCO, SparingVision will be able to finalize the next steps of the clinical validation of an unique therapeutic approach and make the product finally accessible and being the solution to stop unnecessary blindness and other degenerative conditions.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SIROCO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SIROCO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

HAC (2019)

ADVANCED TREATMENT OF CONTAMINATED SOIL

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More